Abstract:Background: Immunotherapies have shown remarkable success in cancer treatment. However, diverse tumor-specific immunosuppressive mechanisms dampen response rates highlighting the need for novel immunotherapeutic targets. Protein Tyrosine Phosphatase Non-Receptor Type 22 (PTPN22) is a phosphatase specific to hematopoietic cells that negatively regulates immune responses. For example, it functions as an early break on T cell activation by dephosphorylating tyrosine residues on Lck and ZAP70 in the T cell receptor signaling cascade. We previously demonstrated that PTPN22 abrogation can enhance antitumor efficacy against immunogenic MC38 tumors. However, it is unclear whether PTPN22 can serve as an immunotherapeutic target in more immune-resistant cancer types. Here, we evaluate the role of PTPN22 in antitumor immunity across tumor models of varying immunogenicity. Methods: We utilized tumor mouse models of varying immunogenicity ranging from the immunogenic lung model CMT167, PD1-responsive and resistant models of hepatocellular carcinoma (HCC) (Hep53.4 and RIL175, respectively), to immune-restricted triple negative breast cancer (TNBC) models (E0771.LMB and 4T1) and highly immunotherapy-resistant pancreatic ductal adenocarcinoma (PDAC) model KPCY6419c5. In addition to genetic abrogation, we tested the antitumor efficacy of pharmacologic inhibition of PTPN22 using L-1, a small molecule inhibitor of PTPN22 we previously developed. Tumors were harvested for tumor microenvironment (TME) analysis using high-parameter suspension and imaging mass cytometry (CyTOF and IMC, respectively). Results: Abrogation of PTPN22 alone or in combination with other immunomodulatory agents led to a substantial reduction in tumor growth as expected in the immunogenic models, CMT167, Hep53.4, but also in the relatively immunosuppressed models, RIL175, E0771.LMB, 4T1, and KPCY 6419c5. Analysis of tumor-infiltrating immune cells revealed an increased infiltration of CD3+ T cells within multiple models upon PTPN22 abrogation. T cell subsets also exhibited increased expression of Granzyme B, PD-1, and co-stimulatory molecules such as CD40, 4-1BB, ICOS indicating improved activation. Conclusions: Collectively, our results show that abrogation of PTPN22 yields improved anti-tumor efficacy in a range of tumor models. Additionally, PTPN22 inhibition functionally remodels T cell subsets by enhancing their activation state within the tumors in the context of varying immunogenicity. Moreover, the reproducibility of anti-tumor efficacy using L-1 suggests the translatability of targeting PTPN22 as an attractive immunotherapeutic strategy. Further work to understand how targeting PTPN22 alters the different immune cell subsets within the distinct tissue environments is warranted. Citation Format: Jayalaxmi Suresh Babu, Soren Charmsaz, Nicole E Gross, Alexei G Hernandez, Courtney D Cannon, Xuan Yuan, Jianping Lin, Zhong-Yin Zhang, Elizabeth M Jaffee, Won Jin Ho. Validating PTPN22 as a cancer-agnostic immunotherapeutic target [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr B003.

Abstract 6233: Characterizing variants of uncertain significance in the tumor suppressor gene known as phosphatase and tensin homolog (PTEN)

Classification of PTEN missense VUS through exascale simulations

Functional analysis of PTEN variants of unknown significance from PHTS patients unveils complex patterns of PTEN biological activity in disease

Abstract 3012: Characterizing the functional significance of "variant of uncertain significance" of the tumour suppressor CDH1

Abstract B003: Validating PTPN22 as a cancer-agnostic immunotherapeutic target

The regulation of PTEN: Novel insights into functions as cancer biomarkers and therapeutic targets

The PTEN Conundrum: How to Target PTEN-Deficient Prostate Cancer

Regulation of the tumor suppressor PTEN by natural anticancer compounds

Decoding PTEN: from biological functions to signaling pathways in tumors

Comprehensive characterization of PTEN mutational profile in a series of 34,129 colorectal cancers

WWP1 Gain-of-Function Inactivation of PTEN in Cancer Predisposition

Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer

Prognostic and Predictive Implications of PTEN in Breast Cancer: Unfulfilled Promises but Intriguing Perspectives

A retrospective analysis suggests PTEN expression is associated with favorable clinicopathological features of breast cancer

Loss of Phosphatase and Tensin Homolog Expression Correlates with Clinicopathological Features of Non-Small Cell Lung Cancer Patients and Its Impact on Survival: A Systematic Review and Meta-Analysis

New Insights into PTEN Regulation Mechanisms and Its Potential Function in Targeted Therapies.

A robust immunohistochemical assay for detecting PTEN expression in human tumors

Unexpected cancer-predisposition gene variants in Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome patients without underlying germline PTEN mutations

P2.02-020 Molecular Characteristics of Patients with PTEN Mutations in Chinese Non-Small Cell Lung Cancer

Clinical, histological and receptor profiles of invasive breast cancer and ductal carcinoma in situ in females with germline pathogenic variants in PTEN and implications for germline testing

Risk Stratification of Prostate Cancer Through Quantitative Assessment of PTEN Loss (Qpten).